Innate Pharma SA

Developing first-in-class antibody immunotherapies for cancer via the innate immune system.

IPHA | US

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 117 AVENUE DE LUMINY, 13009 MARSEILLE
Website:: https://www.innate-pharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Innate Pharma SA is a global, clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system to discover and develop first-in-class antibody-based therapeutics. Its product portfolio consists of a pipeline of clinical-stage assets, including proprietary programs like lacutamab and partnered assets such as monalizumab. Innate Pharma advances its pipeline through both independent development and strategic collaborations with major pharmaceutical partners, with the goal of improving clinical outcomes and providing new treatment options for patients with high unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Innate Pharma SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Innate Pharma SA

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Innate Pharma SA via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Humacyte, Inc. Bioengineering off-the-shelf human tissues for vascular repair and regenerative medicine.	United States of America	HUMA
Human Stem Cells Institute PJSC A biotech investor developing gene therapy, regenerative medicine, and genetic services.	Russian Federation	ISKJ
HUMASIS CO., LTD. Develops & manufactures rapid in-vitro diagnostic test kits & instruments for global POCT markets.	South Korea	205470
Humedix Co., Ltd. Develops hyaluronic acid-based pharma, aesthetics, medical devices, and offers CMO services.	South Korea	200670
HUONS CO., LTD. Global healthcare company providing pharmaceuticals, medical devices, and wellness products.	South Korea	243070
Huons Global Co., Ltd. Develops pharmaceuticals, medical devices, cosmetics, and health foods for the global market.	South Korea	084110
Hutchmed (China) Limited	Hong Kong	HCM
HUTCHMED (China) Ltd Develops and commercializes targeted therapies for cancer and immunological diseases worldwide.	United States of America	HCM
HWAIL PHARM. CO., LTD Develops and manufactures APIs, finished drugs, and functional ingredients for healthcare.	South Korea	061250
Hyloris Pharmaceuticals SA A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.	Belgium	HYL